Define dirty and clean hold times
Account for both pre-cleaning and post-cleaning storage intervals.
CV-REQ-000003
EU GMP Annex 15: Qualification and Validation§ 10.8
TOPIC EXPLORER
Cleaning Validation
A connected view of process design, qualification and continued control.
10 connected references
Include microbial and endotoxin risk
Consider microbial and endotoxin contamination when developing protocols.
CV-REQ-000007
EU GMP Annex 15: Qualification and Validation§ 10.7
Define cleaning responsibilities
Written validation procedures should address responsibilities and acceptance decisions.
CV-REQ-000008
Validation of Cleaning Processes§ General requirements
Prepare a study protocol
Prepare protocols addressing sampling and analytical method sensitivity.
CV-REQ-000009
Validation of Cleaning Processes§ General requirements
Document the validation conclusion
A management-approved report should establish whether cleaning is validated.
CV-REQ-000013
Validation of Cleaning Processes§ General requirements
Describe the cleaning study
Protocols should describe equipment, procedures, criteria and sample collection.
CV-REQ-000015
Q7A: Good Manufacturing Practice for APIs§ 12.7 — protocol
Monitor cleaning after validation
Monitor validated cleaning procedures at appropriate intervals during production.
CV-REQ-000018
Q7A: Good Manufacturing Practice for APIs§ 12.7 — ongoing monitoring
Review the validated state
Periodically evaluate whether systems remain in a valid state.
CV-REQ-000019
Q7A: Good Manufacturing Practice for APIs§ 12.6
Manage the cleaning lifecycle
Connect cleaning development, qualification and ongoing monitoring.
CV-REQ-000024
Cleaning validation guide (GUI-0028)§ 7
Address manual cleaning variability
Control operator-related variability in manual cleaning.
CV-REQ-000025
Cleaning validation guide (GUI-0028)§ 7.1.1
Practical guidance
The State of Cleaning Validation 2026: Five Developments Reshaping the Field
Two years of regulatory revision, enforcement, new standards, tighter analytics and a first serious statistics stack have moved cleaning validation out of the appendix and into the centre of GMP. Five developments define where the field stands in September 2026 — and each one changes something a programme owner has to decide.
The Cleaning Validation Data Shift: From Offline Results to Process Intelligence
At-line TOC, in-line UV and automated process capability monitoring are moving cleaning data from a laboratory result reported days later to a signal produced during the cycle. A close reading of what is proven, what standards actually require, and what remains a promising research proposal.
From Biologics to ADCs: Why New Modalities Are Changing Cleaning Validation
Biologics degrade under cleaning, ADCs split one residue into antibody, linker, payload and conjugate, and peptide APIs combine high potency with methods already under strain. A synthesis of the local evidence on why toxicology, cleaning and detectability now move together.
Visual Clean Is Important — but When Is It Enough?
Visual inspection was present in every one of the cleaning findings FDA issued between 2024 and 2026 — never as the accused technique, always as the whole of the evidence. The distinction between a qualified visual method and a visual-only release decision is the difference between a control and an assumption.
HPLC, LC-MS/MS, TOC, UV or Visual Inspection? Choosing a Cleaning Validation Method by Risk
The analytical method is not a laboratory preference — it is the part of the cleaning validation strategy that decides whether a limit is actually measurable. The useful question is not which technique is 'best' but which technique matches the residue, the acceptance limit, the sampling method and the surface. This analysis walks through the trade-offs using published recovery, detection and clearance data, and shows why a method chosen before the residue is characterised tends to fail at the limit rather than at the bench.
From Three Runs to Lifecycle Control: What Continued Cleaning Verification Really Means
The three-run cleaning validation was never a requirement — it was the convention that grew where guidance was silent. PI 006-4, the ASTM cleaning standards and three recent FDA warning letters all point at the same thing: what has to be maintained is a validated state, and continued cleaning verification is how you know it still holds.
A MACO Is Only as Good as the Assumptions Behind It
A maximum allowable carry-over value is a PDE multiplied by a set of process assumptions — batch size, dose, surface area, recovery and the cleaning step itself. Read as a body of evidence, the 2025–2026 enforcement record is rarely about toxicity assessment, and almost always about those assumptions.
PIC/S Publishes PI 006-4: A New Qualification and Validation Recommendation Takes Effect in October
PIC/S has published PI 006-4, the revised Recommendations on Qualification and Validation, superseding the 2007 PI 006-3 and entering into force on 1 October 2026. Cleaning validation now occupies a full chapter, with HBEL-driven scope, explicit limits on visual inspection and a clear position against continued test-until-clean practice.
FDA Challenges a Visual-Only Cleaning Validation Strategy
A 2026 FDA warning letter to Dabur India rejects a shared-equipment cleaning programme that relied exclusively on visual inspection. The objection is narrower than it appears — and it turns on missing quantitative limits, not on visual inspection itself.
What FDA Has Been Citing in Cleaning Validation: The Recurring Themes of 2025–2026
Twelve FDA warning letters issued between 3 December 2024 and 24 July 2026 cite cleaning and cross-contamination control. Read together rather than case by case, they stop looking like twelve incidents and start looking like one audit checklist: worst-case selection, hold times, recovery, MACO justification, visual-only strategies, sampling locations, change control and lifecycle management — in that order of frequency.
Annex 15 Corrigendum: Small Text, Big Consequences for Cleaning Teams
EMA and PIC/S reissued the January 2026 Annex 15 concept paper in July 2026 with a new reference number and a substantially longer timetable. Nothing about cleaning validation itself changed — but the dates most teams are planning against did.
ADCs Are Creating a New Cleaning Validation Problem
Antibody-drug conjugates combine a biologic, a chemical linker and a cytotoxic payload on shared equipment. A STERIS webinar frames the problem; independent guidance shows why one product-specific assay no longer answers the question.
Peptide APIs Put Cleaning Limits Under the Microscope: FDA Cites Missing MACO for Semaglutide and Tirzepatide
FDA's 1 May 2026 warning letter to Harbin Jixianglong Biotech found a cleaning procedure that required a toxicity-based carryover limit, and a validation study that established none — with no justification for swab locations and no swab results.
Worst Case or Product-Specific? New Research Reopens the Cleaning Validation Strategy Debate
A comparative review in the PDA Journal weighs worst-case matrices against product-specific validation and proposes a hybrid model anchored on visible residue limits.
Released as Clean, Yet Residue Remained: A Simple Finding With a Bigger System Lesson
An FDA investigator found white residue inside Tank #68 at Chemco Corporation — equipment the quality unit had already verified as clean. The finding itself is mundane. What it exposes about release decisions, shared equipment and the absence of cleaning validation is not.
EU and PIC/S Start the Next Revision of Annex 15 — What Validation Teams Should Watch
A joint EMA–PIC/S concept paper proposes extending Annex 15 to active substance manufacturers and aligning it with ICH Q9(R1). The current Annex 15 stays in force, and the earliest a revised text could be published is 2028.
Can a Cleaning Validation Demonstrate Reproducibility If Every Run Samples Somewhere Different?
FDA's Warning Letter 320-26-43 to Cosmetic Manufacturers (Aust) Pty Ltd. states that the firm's cleaning validation protocol 'was not designed to demonstrate reproducibility'. The cause is a design flaw that is easy to copy by accident: each qualification run sampled a different set of locations, so the runs were never replicates of the same measurement.
A Cleaning Verification Programme Is Only Useful If It Can Detect the Risk
FDA Warning Letter 320-26-40 to Cohance Lifesciences did not turn on a single residue number. It turned on whether the firm's verification programme could have found the carryover at all — and whether its worst-case basis was ever revisited.
AI Enters Continued Cleaning Process Verification — but the Statistics Come First
A January 2026 AAPS PharmSciTech paper proposes normalising every residue result to a percentage of its own specification limit, so that cleaning data from different products can finally be pooled, analysed non-parametrically and monitored as a Stage 3 capability index. The statistical argument is the substance; the AI framing is thinner than the title suggests.
When the Cleaning Validation No Longer Matches the Factory
FDA's December 2025 letter to Medinatura New Mexico records a firm acknowledging that its cleaning validation was not reflective of current operations after years of buying new equipment and adding new products. What the gap looks like from the inside — and what it asks of change control.
Cleaning Validation Is Becoming an Operational Strategy, Not Just a Compliance Exercise
A BeNeLux ISPE event on 23 September 2025 put 'business continuity' and 'culture' next to 'compliance' in the same talk title. That framing is the story: cleaning validation is being repositioned as an operational capability that keeps multi-product campaigns running, not a documentation obligation discharged before an inspection.
A Cleaning Validation Can Age: What Happens When Products Change but the Study Does Not
The FDA's August 2025 warning letter to ABBE Laboratories describes a 2009 cleaning validation still standing while a harder-to-clean product was introduced onto the same shared kettle — and no change-control step that caught it.
Can Cleaning Be Monitored in Real Time? In-Line UV Moves Validation Closer to PAT
A STERIS-authored article in Pharmaceutical Technology reports that in-line UV spectrometry at 220 nm can follow a biopharmaceutical cleaning cycle continuously, from heavily soiled rinse to baseline. The data are encouraging, the framing is vendor-supplied, and the distance between process monitoring and a release decision is where our own thinking has to do the work.
Should Cleaning Validation Extend Into the QC Laboratory?
A 2025 DARU Journal of Pharmaceutical Sciences study builds a structured cleaning-validation protocol for QC-lab glassware and stainless-steel equipment, using oxcarbazepine as worst-case API and pairing HPLC residue analysis with conductivity and TOC detergent checks.
ASTM E3470-25: Cleaning Risk Management Gets a Dedicated Method Standard
ASTM International has published E3470-25, a first-edition guide on using FMECA and HACCP/HARPC to identify, analyse and control risk in pharmaceutical and medical device cleaning processes. It is the method layer that E3106 required but did not fully specify.
ASTM Updates Its HBEL Guide: What E3219-25 Means for Cleaning Validation
ASTM has re-issued E3219 as E3219-25, the current reference for deriving health-based exposure limits. HBELs are a decade-old regulatory expectation, not a 2025 novelty — but the revision sharpens how limits are derived, documented and defended.
Lab, At-Line, Online, In-Line: Where Does TOC Fit?
TOC can live on the QC bench, on the shop floor next to the vessel, or plumbed into the CIP skid. The instrument is the same; the sampling chain — and therefore the meaning of the number — is not.
Do Cleaning Validation Programmes Need Every Analytical Test They Currently Run?
A lightning talk at PDA Week 2025 argued for a lean approach to analytical panels in cleaning validation. The independent framework to justify it already exists in ASTM E3106 and ICH Q9(R1) — but only if the arithmetic is documented.
INTERPHEX 2025: Process Monitoring Reaches the Cleaning Suite
INTERPHEX 2025 in New York put cleaning validation on the process-monitoring agenda: a dedicated panel on analytics, contamination control and sustainability, plus cleanroom and environmental-monitoring sessions. Industry-press report from Javits Center, 1-3 April 2025.
What Does 'Clean' Mean When Equipment Status and Physical Condition Disagree?
A March 2025 FDA warning letter to Aspen Biopharma Labs Private Limited records investigators finding manufacturing equipment labelled "Cleaned" while liquid with a floating substance or residue remained on product-contact surfaces. That gap between a status tag and physical reality is one of the most consequential — and most preventable — failures in cleaning validation.
When MACO Is Not Enough: What the Granules India Warning Letter Really Teaches
The FDA rejected a retrospective MACO argument in a February 2025 warning letter — not because the arithmetic was wrong, but because the cleaning it assumed had not been performed. What cleaning-validation teams can take from it.
Visual Inspection Alone Was Not Enough: What FDA Expected to See
In Warning Letter 320-25-38 the FDA did not attack visual inspection as a technique. It objected to a cleaning programme in which visual inspection was the only evidence on the table — no acceptance criteria for carryover residues, no analytical data, and no procedures for the rest of the equipment train.
Cleaning Validation Meets Waste Treatment: A Study of SGLT-2 Inhibitor Residues
A NIPER-Ahmedabad group pairs a validated RP-HPLC surface-residue method for three SGLT-2 inhibitors with a detoxification strategy for the resulting cleaning waste.
FDA Again Links Shared Equipment to the Need for a Lifecycle Cleaning Programme
A December 2024 warning letter to Brands International Corporation cites the firm under 21 CFR 211.67(b) for failing to perform cleaning validation studies on non-dedicated equipment — and asks for a cleaning programme built around worst-case products, worst-case swab sites and maximum hold times before cleaning.
When Shared Equipment Has Never Been Cleaning-Validated: Lessons From an FDA Warning Letter
An FDA Warning Letter to Indian API manufacturer Micro Orgo Chem describes non-dedicated equipment that had never been cleaned under a validated procedure, cleaning SOPs that were not followed, and no evidence that the rinse and swab samples required by the firm's own procedure were ever collected or tested.
ASTM Puts Process Capability on the Cleaning Validation Agenda
ASTM work item WK92658 wants to standardise how cleaning processes are judged capable — one-sided limits, small data sets, non-normal residues and continued verification included. It is the statistical gap E3106 left open.
What Happens to Biologics During Cleaning? New Data on Cleaning-Induced Protein Degradants
A bench-scale study puts the 650 ug/dose parenteral PDE for cleaning-induced protein degradants to the test with human-cell immunogenicity assays on HLE BiTE and mAb degradants, spiked into the same and a cross product.
ASTM Moves Toward Dedicated Guidance for TOC in Cleaning Validation
ASTM Work Item WK92599 would give total organic carbon analysis its own dedicated guidance for swab and rinse samples — and force cleaning programmes to defend recovery and limits, not just concentrations.
Cleaning Validation Beyond Manufacturing Vessels: What About Blister Packaging?
A German hospital-pharmacy study argues blister-machine cleaning is a mandatory duty of care, and shows UV-Vis spectroscopy can replace HPLC as the analytical method.